Evidence map›Paper›PMID 33338321›Full record

ArticleMolecular oncology2021

Immune response drives outcomes in prostate cancer: implications for immunotherapy.

Jialin Meng, Yujie Zhou, Xiaofan Lu, Zichen Bian, Yiding Chen, Jun Zhou, Li Zhang, Zongyao Hao, Meng Zhang, Chaozhao Liang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jialin MengDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.ORCID 0000-0002-4622-833X
Yujie ZhouDivision of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, China.
Xiaofan LuState Key Laboratory of Natural Medicines, Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, China.
Zichen BianDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Yiding ChenDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Jun ZhouDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Li ZhangDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Zongyao HaoDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Meng ZhangDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Chaozhao LiangDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The heterogeneity of the immune microenvironment leads to different responses in immune checkpoint blockade therapy. We aimed to propose a robust molecular classification system to investigate the relevance of the immune microenvironment subtype and prognosis of prostate cancer patients, as well as the therapeutic response to immune checkpoint blockade therapy. A total of 1,557 prostate cancer patients were enrolled, including 69 real-world samples from our institute (titled the AHMU-PC cohort). The non-negative matrix factorization algorithm was employed to virtually microdissect patients. The immune enrichment was characterized by a high enrichment of T cell-, B cell-, NK cell-, and macrophage-associated signatures, by which patients were subclassified into nonimmune and immune classes. Subsequently, the immune class was dichotomized into immune-activated and immune-suppressed subtypes based on the stromal signature, represented by the activation of WNT/TGF-β, TGF-β1, and C-ECM signatures. Approximately 14.9% to 24.3% of patients belonged to the immune-activated subtype, which was associated with favorable recurrence-free survival outcomes. In addition, patients in the immune-activated subtype were predicted to benefit more from anti-PD-1/PD-L1 therapy. In conclusion, our study identifies a novel immune molecular classifier that is closely related to clinical prognosis and provides novel insights into immunotherapeutic strategies for prostate cancer patients.

Indexed as

AdenocarcinomaAgedBiomarkers, TumorCohort StudiesGene Expression Regulation, NeoplasticHumansImmunityImmunotherapyKiller Cells, NaturalLymphocytes, Tumor-InfiltratingMaleMiddle AgedPrognosisProstatic NeoplasmsTreatment OutcomeTumor MicroenvironmentBiomarkers, Tumorimmune checkpoint blockade therapyimmune molecular subclassification systemimmunotherapynon-negative matrix factorizationprostate cancer

Identifiers

PMID33338321
PMCPMC8096785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.